Compare APLE & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APLE | TMDX |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.5B |
| IPO Year | 2007 | 2019 |
| Metric | APLE | TMDX |
|---|---|---|
| Price | $15.95 | $74.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $13.00 | ★ $148.22 |
| AVG Volume (30 Days) | ★ 2.3M | 1.4M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 7.12% | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | 0.12 | ★ 0.20 |
| Revenue | ★ $1,238,622,000.00 | $605,494,000.00 |
| Revenue This Year | $2.31 | $24.25 |
| Revenue Next Year | $2.35 | $18.75 |
| P/E Ratio | ★ $129.96 | $355.70 |
| Revenue Growth | 18.98 | ★ 37.13 |
| 52 Week Low | $10.85 | $60.11 |
| 52 Week High | $15.81 | $156.00 |
| Indicator | APLE | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 77.51 | 48.93 |
| Support Level | $11.50 | $64.90 |
| Resistance Level | N/A | $120.60 |
| Average True Range (ATR) | 0.33 | 3.91 |
| MACD | 0.07 | 2.21 |
| Stochastic Oscillator | 96.78 | 92.52 |
Apple Hospitality REIT Inc is a real estate investment trust that invests in income-producing real estate, majorly in the lodging sector, in the United States. It chiefly invests in upscale service hotels. All of the company's hotels operate under the Marriott or Hilton brands. Apple Hospitality has wholly-owned taxable REIT subsidiaries, which lease all of the company's hotels from wholly-owned qualified REIT subsidiaries. These hotels are managed under separate agreements with various hotel management companies that are unaffiliated with Apple Hospitality. The company derives its income from hotel revenue, its sole segment.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.